The immune system has crucial roles in cancer development and treatment. Whereas
adaptive immunity can prevent or constrain cancer through immunosurveillance, innate …

Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …

In population studies, dietary patterns clearly influence the development, progression, and
therapeutic response of cancers. Nonetheless, interventional dietary trials have had …

Background The use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an
increase in immune-related adverse events (irAEs), which can cause treatment …

Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several
cancer types. However, systemic activation of the immune system also leads to several …

Abstract Background Immune checkpoint inhibitors (ICIs) often cause immune-related
adverse events (irAEs), most of which are treated with corticosteroids despite evidence …

Background Vitamin D3 is a prohormone with pleiotropic effects, including modulating the
functions of the immune system and may affect the effectiveness of anti–PD‐1 treatment in …

Cancer patients treated with immune checkpoint inhibitors (ICIs) are susceptible to a broad
and variable array of immune‐related adverse events (irAEs). With increasing clinical use of …

Immune checkpoint inhibitors (ICIs) have opened up a new way for tumor therapy but
simultaneously led to the occurrence of immune-related adverse events. We report a case of …

Cancer immunotherapy has revolutionized the treatment of advanced cancers and is quickly
becoming an option for early‐stage disease. By reactivating the host immune system …